Celyad Oncology S.A.

For H1 2023, Celyad reported research and development expenses of EUR 2.1 million versus EUR 10.5 million in H1 2022, a decrease of EUR 8.4 million. General and administration expenses were EUR 3.7 million versus EUR 6.2 million in H1 2022, down EUR 2.5 million. Net other income was EUR 2.1 million, compared with EUR 1.6 million in H1 2022, driven mainly by a EUR 1.1 million gain on the sale of fixed assets to Cellistic and EUR 0.8 million of grant income from the Walloon Region. Net loss was EUR 3.7 million, or EUR 0.17 per share, versus a net loss of EUR 14.1 million, or EUR 0.62 per share a year earlier. Net cash used in operations was EUR 8.3 million, compared with EUR 16.3 million in H1 2022, and cash and cash equivalents were EUR 5 million as of June 30, 2023. Management said the EUR 9.8 million private placement commitments, together with existing cash, should fund operating expenses and capex until the end of Q4 2024 / end of 2024.

Georges Rawadi framed the company as having completed a strategic reset and now being focused on next-generation CAR T-cell therapies and the value of its proprietary engineering platform, targets and IP. He said the company aims to stay at the forefront of CAR T development and to address key limitations of current CAR T therapies, especially in broader cancer indications including solid tumors. His tone was confident and forward-looking, with multiple references to upcoming milestones, conferences, and potential strategic partnerships.

David Georges highlighted substantial year-over-year cost reductions driven by the end of manufacturing activities, discontinuation of some preclinical and clinical programs, and lower headcount-related costs after the 2022 reorganization. He cited R&D of EUR 2.1 million, G&A of EUR 3.7 million, net loss of EUR 3.7 million, and operating cash burn of EUR 8.3 million for H1 2023, all materially below H1 2022. He also noted no change in the fair value of contingent consideration and other financial liabilities because no sublicense or collaboration event made the probability of future cash outflow higher, and said the EUR 9.8 million private placement should help fund the company through Q4 2024.

There were no analyst questions on the call, so management did not address any live follow-up on financing, pipeline timing, or the reported cost structure. The operator explicitly said no questions were present, and the call ended without a Q&A segment. As a result, the only additional color came from management’s prepared remarks about runway, upcoming scientific presentations, and a planned move to a new research facility.